Table 2

Intervention effectiveness, stratified by disease and baseline disease control

Adjusted OR (95% CI)P valueInteraction
Diabetes (n=73 (543))2.69 (0.72 to 10.14)0.14
 Not controlled at baseline (n=54 (417))5.35 (0.89 to 32.17)0.070.49
 Controlled at baseline* (n=15 (109))1.46 (0.06 to 37.26)0.82
Hypertension (n=117 (869))3.18 (1.55 to 6.55)0.002
 Not controlled at baseline (n=48 (364))6.28 (1.79 to 22.06)0.0040.29
 Controlled at baseline† (n=62 (486))2.65 (0.99 to 7.12)0.053
  • Individual-level mixed effects analysis adjusting for time and cohort with random intercepts to account for clustering by individual and community (n=number of individual patients (number of time points)). Four patients with diabetes and seven patients with hypertension not included in stratified analysis due to missing baseline control data.

  • *Defined as glycated haemoglobin (HbA1c) <7%.

  • †Defined as blood pressure (in mm Hg) <140/90, <130/80 if concomitant diabetes, <150/90 if age ≥80 according to 2010/2014 Mexican Ministry of Health guidelines.17